Acrivon Therapeutics, Inc.
ACRV evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ACRV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACRV
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology therapies, including ACR-368 and ACR-2316, guided by its proprietary OncoSignature platform. The company has no approved products and has incurred significant operating losses, with an accumulated deficit of $293.9 million as of March 31, 2026.
Key risk: Capital Need and Dilution Risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 2 clinical trials for Acrivon Therapeutics, Inc..
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology therapies, including ACR-368 and ACR-2316, guided by its proprietary OncoSignature platform. The company has no approved products and has incurred significant operating losses, with an accumulated deficit of $293.9 million as of March 31, 2026.
- Acrivon's lead candidates are ACR-368 (a CHK1/2 inhibitor) and ACR-2316 (a WEE1/PKMYT1 inhibitor), both in clinical development [sec_mda · as of 2026-08-12].
- The company uses a proprietary OncoSignature platform to identify patients most likely to respond to its therapies [sec_mda · as of 2026-08-12].
- As of June 30, 2026, Acrivon reported cash and equivalents of $41.6 million and a net loss of $18.0 million for the quarter [sec].
- The company has an accumulated deficit of $293.9 million as of March 31, 2026, and expects to continue incurring significant operating losses [sec_mda · as of 2026-05-13].
- Acrivon will need to raise substantial additional capital to fund its ongoing and planned clinical trials and other operations [sec_mda · as of 2026-08-12].
What works
- Acrivon's OncoSignature platform is designed to match drug candidates with biomarker-defined patient populations, potentially increasing clinical trial success rates [sec_mda · as of 2026-08-12].
- The company has two clinical-stage assets, ACR-368 and ACR-2316, targeting distinct but complementary DNA damage response pathways [sec_mda · as of 2026-08-12].
- Acrivon raised $123.8 million in net proceeds from an April 2024 PIPE, providing a capital base to advance its pipeline [sec_mda · as of 2025-11-13].
What to weigh
- Acrivon has no approved products and has never generated revenue from drug sales; its accumulated deficit was $293.9 million as of March 31, 2026 [sec_mda · as of 2026-05-13].
- The company expects to need substantial additional capital, and its ability to raise funds may be adversely impacted by global economic conditions [sec_mda · as of 2026-08-12].
- Clinical development timelines and costs are inherently unpredictable, and the company may face delays or failures in its trials [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
Acrivon has an accumulated deficit of $293.9 million as of March 31, 2026.
“As of March 31, 2026, we had an accumulated deficit of $293.9 million.”
SEC MD&A · May 13, 2026
The company will need to raise substantial additional capital.
“We will need to raise substantial additional capital in the future.”
SEC MD&A · August 12, 2026
The company prioritizes investment in activities expected to generate near-term value, including key data readouts.
“We continue to prioritize investment in activities expected to generate the most significant near-term value, including completion of ongoing clinical studies and key data readouts.”
SEC MD&A · August 12, 2026
Risks & what to watch (4)›
Key risks
- Capital Need and Dilution Risk — Acrivon will need to raise substantial additional capital; failure to do so may delay or halt development [sec_mda · as of 2026-08-12].
- Clinical Trial Uncertainty — Clinical development timelines and costs are unpredictable; trials may fail or be delayed [sec_mda · as of 2026-08-12].
- No Approved Products or Revenue — The company has no approved drugs and has never generated revenue from product sales [sec_mda · as of 2026-03-19].
- Reliance on OncoSignature Platform — The success of the pipeline depends on the predictive accuracy of the proprietary OncoSignature platform [sec_mda · as of 2026-08-12].
What to watch
- Completion of ongoing clinical studies for ACR-368 and ACR-2316 and associated data readouts [sec_mda · as of 2026-08-12].
- Initiation of IND-enabling studies for ACR-6840 [sec_mda · as of 2026-03-19].
- Ability to raise additional capital through equity or debt offerings [sec_mda · as of 2026-08-12].
- Regulatory developments and updates on the company's cash runway [sec_mda · as of 2026-08-12].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Acrivon Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Acrivon Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
17.8 months
D/E 0.14 · 0% dilution
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
0 buys · 8 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
43
Total value held
$19.2M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 8,340,508 | $11.6M |
| vanguard capital management llc | 1,444,070 | $2.0M |
| wellington management group llp | 888,130 | $1.2M |
| renaissance technologies llc | 758,440 | $1.1M |
| marshall wace, llp | 560,436 | $779K |
| two sigma investments, lp | 389,395 | $541K |
| jane street group, llc | 239,691 | $333K |
| geode capital management, llc | 236,391 | $329K |
| blackrock, inc. | 208,939 | $290K |
| bridgeway capital management, llc | 158,900 | $221K |
Showing top 10 of 43 institutional holders of Acrivon Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 12.5%
- Days to cover
- 3.9
- Shares short
- 2,388,157
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ACRV short interestGovernance
Frequently asked questions
What is the AI investment thesis for Acrivon Therapeutics, Inc.?
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology therapies, including ACR-368 and ACR-2316, guided by its proprietary OncoSignature platform. The company has no approved products and has incurred significant operating losses, with an accumulated deficit of $293.9 million as of March 31, 2026.
What is Acrivon Therapeutics, Inc.'s lead drug candidate?
Acrivon Therapeutics, Inc.'s most advanced tracked candidate is ACR-2316 (Phase 1) for Specific Advanced Solid Tumors.
Who is the CEO of Acrivon Therapeutics, Inc.?
Dr. Peter Blume-Jensen M.D., Ph.D. is the chief executive officer of Acrivon Therapeutics, Inc. (ACRV).
Where is Acrivon Therapeutics, Inc. headquartered?
Acrivon Therapeutics, Inc. (ACRV) is headquartered in Watertown, MA, United States.
What therapeutic areas does Acrivon Therapeutics, Inc. focus on?
Acrivon Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.